Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Tianjin JuveStar Enters $74 Million Deal with Raziel for Body Fat Treatment

publication date: Sep 18, 2020

Tianjin JuveStar Biotech, a Fosun Pharma affiliate, acquired Greater China rights to an aesthetic product from Israel's Raziel Therapeutics in a $74 million agreement. RZL-012 is an injectable drug initially indicated to treat moderate to significant submental fullness, known commonly as a double-chin. Raziel expects to test the product in other body fat indications in the future. Fosun has invested in JuveStar and is incubating the company. More details....

Stock Symbols: (SHA: 600196; HK: 02196)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.